Skip to main content
SpringerLink
Log in

Breast Cancer

  • Reference work entry
  • First Online:
Geriatric Medicine

  • 388 Accesses

Abstract

Breast cancer is a disease of aging, and most breast cancer cases and deaths worldwide occur among older adults. The last decades have brought an unprecedented growth in knowledge regarding the molecular bases of breast cancer, which has been followed by an increase in the number of available treatment options and strategies. Unfortunately, in many cases, the available information to treat older women with breast cancer is limited, and there is still a lack of high quality evidence regarding the risks and benefits of treatment in the older population, particularly in those who are vulnerable or frail. In this chapter, we provide an overview of the epidemiology of breast cancer in older adults, on the existing evidence regarding the various available treatment options, on the relevance of shared decision making and outcome prioritization, and on practical ways in which to implement geriatric principles to the care of older women with breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F. Global cancer observatory: cancer today. Lyon: International Agency for Research on Cancer; 2018. Available from: https://gco.iarc.fr/today, Accessed April 4 2019.

    Google Scholar 

  2. Pandya S, Moore RG. Breast development and anatomy. Clin Obstet Gynecol. 2011;54(1):91–5.

    Article  PubMed  Google Scholar 

  3. Drew PCS, Michell M. Interventional ultrasound of the breast anatomy of the breast by Menos Lagopoulos. London: Informa Healthcare; 2007. p. 11–22.

    Book  Google Scholar 

  4. Greenfield LMM, Oldham K. Surgery: scientific principles and practice. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2001.

    Google Scholar 

  5. Moore KPT. The developing human – clinically oriented embryology. 6th ed. Philadelphia: WB Saunders Company; 1998.

    Google Scholar 

  6. Brunicardi FAD, Billiar T. Schwartz’s principles of surgery. 8th ed. New York: The McGraw-Hill Medical Publishing Division; 2004.

    Google Scholar 

  7. Pilleron S, Sarfati D, Janssen-Heijnen M, Vignat J, Ferlay J, Bray F, et al. Global cancer incidence in older adults, 2012 and 2035: a population-based study. Int J Cancer. 2019;144(1):49–58.

    Article  CAS  PubMed  Google Scholar 

  8. Arnold M, Pandeya N, Byrnes G, Renehan AG, Stevens GA, Ezzati M, et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 2015;16(1):36–46.

    Article  PubMed  Google Scholar 

  9. Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016;4(9):e609–16.

    Article  PubMed  Google Scholar 

  10. Ferlay J, et al. GLOBOCAN 2012 v1.1, cancer incidence and mortality worldwide: IARC CancerBase. Lyon: International Agency for Research on Cancer; 2014. Available from: http://globocan.iarc.fr.

  11. Pilleron S, Soerjomataram I, Soto-Perez-de-Celis E, Ferlay J, Vega E, Bray F, et al. Aging and the cancer burden in Latin America and the Caribbean: time to act. J Geriatric Oncol. 2019;10(5):799–804.

    Article  Google Scholar 

  12. Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER cancer statistics review, 1975–2015. Bethesda: National Cancer Institute. https://seer.cancer.gov/csr/1975_2015/, based on November 2017 SEER data submission, posted to the SEER web site, April 2018.

  13. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100(14):8418–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al. Tailoring therapies – improving the management of early breast cancer: St Gallen International Expert Consensus on the primary therapy of early breast cancer 2015. Ann Oncol. 2015;26(8):1533–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5)

    Google Scholar 

  16. Jenkins EO, Deal AM, Anders CK, Prat A, Perou CM, Carey LA, et al. Age-specific changes in intrinsic breast cancer subtypes: a focus on older women. Oncologist. 2014;19(10):1076–83.

    Article  PubMed  PubMed Central  Google Scholar 

  17. DuMontier C, Loh KP, Bain PA, Silliman RA, Hshieh T, Abel GA, et al. Defining undertreatment and overtreatment in older adults with cancer: a scoping literature review. J Clin Oncol. 2020:Jco1902809.

    Google Scholar 

  18. Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen ML, Extermann M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32(24):2595–603.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Mohile SG, Dale W, Somerfield MR, Schonberg MA, Boyd CM, Burhenn PS, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J Clin Oncol. 2018;36(22):2326–47.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, et al. Breast cancer, version 4.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2018;16(3):310–20.

    Article  Google Scholar 

  21. Oncology. NCPGi. Older adult Oncology. 2020. Updated February 7, 2020. Available from: https://www.nccn.org/professionals/physician_gls/pdf/senior.pdf.

  22. Ferrat E, Paillaud E, Caillet P, Laurent M, Tournigand C, Lagrange JL, et al. Performance of four frailty classifications in older patients with cancer: prospective elderly cancer patients cohort study. J Clin Oncol. 2017;35(7):766–77.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Bunn F, Goodman C, Russell B, Wilson P, Manthorpe J, Rait G, et al. Supporting shared decision making for older people with multiple health and social care needs: a realist synthesis. BMC Geriatr. 2018;18(1):165.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Hamelinck VC, Bastiaannet E, Pieterse AH, van de Velde CJH, Liefers GJ, Stiggelbout AM. Preferred and perceived participation of younger and older patients in decision making about treatment for early breast cancer: a prospective study. Clin Breast Cancer. 2018;18(2):e245–e53.

    Article  PubMed  Google Scholar 

  25. Mandelblatt J, Kreling B, Figeuriedo M, Feng S. What is the impact of shared decision making on treatment and outcomes for older women with breast cancer? J Clin Oncol. 2006;24(30):4908–13.

    Article  PubMed  Google Scholar 

  26. Duckworth KE, Morrell R, Russell GB, Powell B, Canzona M, Lichiello S, et al. Goals and adverse effects: rate of concordance between patients and providers. J Oncol Pract. 2019;15(9):e798–806.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Fried TR, Bradley EH, Towle VR, Allore H. Understanding the treatment preferences of seriously ill patients. N Engl J Med. 2002;346(14):1061–6.

    Article  PubMed  Google Scholar 

  28. 5th Symposium on Primary Breast Cancer in Older Women. Future Oncology. 2019;15(7s).

    Google Scholar 

  29. De Celis ESP, Li D, Kim H, Sun C, Sedrak M, Fakih M, et al. Patient-defined preferences and health outcome prioritization among older adults with cancer starting chemotherapy. Journal of Geriatric Oncology. 2019;10(6):S27.

    Article  Google Scholar 

  30. Magnuson A, Dale W, Mohile S. Models of care in geriatric oncology. Curr Geriatrics Rep. 2014;3(3):182–9.

    Article  CAS  Google Scholar 

  31. Shahrokni A, Kim SJ, Bosl GJ, Korc-Grodzicki B. How we care for an older patient with cancer. J Oncol Pract. 2017;13(2):95–102.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Loh KP, Soto-Perez-de-Celis E, Hsu T, de Glas NA, Battisti NML, Baldini C, et al. What every oncologist should know about geriatric assessment for older patients with cancer: young International Society of Geriatric Oncology Position Paper. J Oncol Pract. 2018;14(2):85–94.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Verduzco-Aguirre HC, Navarrete-Reyes AP, Chavarri-Guerra Y, Ávila-Funes JA, Soto-Perez-de-Celis E. The effect of a geriatric oncology clinic on treatment decisions in Mexican older adults with cancer. J Am Geriatr Soc. 2019;67(5):992–7.

    Article  PubMed  Google Scholar 

  34. Li D, Sun C-L, Kim H, Chung V, Koczywas M, Fakih M, Chao J, Chien L, Charles K, Hughes SFDS, Trent M, Roberts E, De Celis ESP, Jayani R, Katheria V, Moreno J, Kelly C, Sedrak MS, Hurria A, Dale W. Geriatric assessment-driven intervention (GAIN) on chemotherapy toxicity in older adults with cancer: a randomized controlled trial. Proc Am Soc Clin Oncol. 2020.

    Google Scholar 

  35. Supriya Gupta Mohile MRM, Culakova E, Xu H, Loh KP, Magnuson A, Flannery MA, Ramsdale EE, Dunne RF, Gilmore N, Obrecht S, Patil A, Plumb S, Lowenstein LM, Janelsins MC, Mustian KM, Hopkins JO, Berenberg JL, Gaur R, Dale W. A geriatric assessment (GA) intervention to reduce treatment toxicity in older patients with advanced cancer: A University of Rochester Cancer Center NCI community oncology research program cluster randomized clinical trial (CRCT). American Society of Clinical Oncology. 2020 (ASCO Meeting Library).

    Google Scholar 

  36. Wee-Kheng Soo MK, Pope A, Parente P, Darzins P, Davis ID. Integrated geriatric assessment and treatment (INTEGERATE) in older people with cancer planned for systemic anticancer therapy. American Society of Clinical Oncology. 2020 (ASCO Meeting Library).

    Google Scholar 

  37. Mohile SG, Epstein RM, Hurria A, Heckler CE, Duberstein P, Canin BE, et al. Improving communication with older patients with cancer using geriatric assessment (GA): a University of Rochester NCI Community Oncology Research Program (NCORP) cluster randomized controlled trial (CRCT). J Clin Oncol. 2018;36(suppl 18):LBA10003-LBA.

    Article  Google Scholar 

  38. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151(10):716–26, w-236.

    Google Scholar 

  39. Oeffinger KC, Fontham ET, Etzioni R, Herzig A, Michaelson JS, Shih YC, et al. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA. 2015;314(15):1599–614.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. The benefits and harms of breast cancer screening: an independent review. Lancet 2012;380(9855):1778–86.

    Google Scholar 

  41. Nelson HD, Fu R, Cantor A, Pappas M, Daeges M, Humphrey L. Effectiveness of breast cancer screening: systematic review and meta-analysis to update the 2009 U.S. Preventive Services Task Force recommendation. Ann Intern Med. 2016;164(4):244–55.

    Article  PubMed  Google Scholar 

  42. Lee CS, Moy L, Joe BN, Sickles EA, Niell BL. Screening for breast cancer in women age 75 years and older. AJR Am J Roentgenol. 2018;210(2):256–63.

    Article  PubMed  Google Scholar 

  43. Devitt JE. Benign disorders of the breast in older women. Surg Gynecol Obstet. 1986;162(4):340–2.

    CAS  PubMed  Google Scholar 

  44. Holmes CE, Muss HB. Diagnosis and treatment of breast cancer in the elderly. CA Cancer J Clin. 2003;53(4):227–44.

    Article  PubMed  Google Scholar 

  45. Morrow M. Breast disease in elderly women. Surg Clin North Am. 1994;74(1):145–61.

    Article  CAS  PubMed  Google Scholar 

  46. Klepin H, Mohile S, Hurria A. Geriatric assessment in older patients with breast cancer. J Natl Compr Cancer Netw. 2009;7(2):226–36.

    Article  Google Scholar 

  47. Singletary SE, Shallenberger R, Guinee VF. Breast cancer in the elderly. Ann Surg. 1993;218(5):667–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Tang V, Zhao S, Boscardin J, Sudore R, Covinsky K, Walter LC, et al. Functional status and survival after breast cancer surgery in nursing home residents. JAMA Surg. 2018.

    Google Scholar 

  49. Hind D, Wyld L, Reed MW. Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: cochrane review. Br J Cancer. 2007;96(7):1025–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Biganzoli L, Wildiers H, Oakman C, Marotti L, Loibl S, Kunkler I, et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol. 2012;13(4):e148–60.

    Article  PubMed  Google Scholar 

  51. Martelli G, Boracchi P, De Palo M, Pilotti S, Oriana S, Zucali R, et al. A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer: results after 5 years of follow-up. Ann Surg. 2005;242(1):1–6; discussion 7–9.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Rudenstam CM, Zahrieh D, Forbes JF, Crivellari D, Holmberg SB, Rey P, et al. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group trial 10–93. J Clin Oncol. 2006;24(3):337–44.

    Article  PubMed  Google Scholar 

  53. Chung A, Gangi A, Amersi F, Zhang X, Giuliano A. Not performing a sentinel node biopsy for older patients with early-stage invasive breast cancer. JAMA Surg. 2015;150(7):683–4.

    Article  PubMed  Google Scholar 

  54. Giuliano AE, Ballman K, McCall L, Beitsch P, Whitworth PW, Blumencranz P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 randomized trial. Ann Surg. 2016;264(3):413–20.

    Article  PubMed  Google Scholar 

  55. Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–10.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Wanebo HJCB, Chung. Is surgical management compromised in elderly patients with breast cancer? Ann Surg. 1997;225:579–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Morrow M, White J, Moughan J, Owen J, Pajack T, Sylvester J, et al. Factors predicting the use of breast-conserving therapy in stage I and II breast carcinoma. J Clin Oncol. 2001;19(8):2254–62.

    Article  CAS  PubMed  Google Scholar 

  58. Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31(19):2382–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM, Investigators PI. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015;16(3):266–73.

    Article  PubMed  Google Scholar 

  60. Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362(6):513–20.

    Article  CAS  PubMed  Google Scholar 

  61. Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM, et al. The UK standardisation of breast radiotherapy (START) trial a of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008;9(4):331–41.

    Article  CAS  PubMed  Google Scholar 

  62. Levy ARS. 1-week hypofractionated adjuvant whole-breast radiotherapy: towards a new standard? Lancet. 2020;395(10237):1588–9.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Jolly T, Williams GR, Jones E, Muss HB. Treatment of metastatic breast cancer in women aged 65 years and older. Womens Health (Lond). 2012;8(4):455–69; quiz 70–1.

    Article  CAS  PubMed  Google Scholar 

  64. Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol. 2006;24(18):2750–6.

    Article  PubMed  Google Scholar 

  65. Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009;360(20):2055–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. von Minckwitz G, Reimer T, Potenberg J, Conrad B, Schürer U, Eidtmann H, et al. Abstract S3-04: the phase III ICE study: adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer. Cancer Res. 2015;75(Suppl 9):S3-04-S3.

    Google Scholar 

  67. Perrone F, Nuzzo F, Di Rella F, Gravina A, Iodice G, Labonia V, et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Ann Oncol. 2015;26(4):675–82.

    Article  CAS  PubMed  Google Scholar 

  68. Colleoni M, Price KN, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A. Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil. International Breast Cancer Study Group. Lancet. 1999;354(9173):130–1.

    Article  CAS  PubMed  Google Scholar 

  69. Muss HB, Berry DA, Cirrincione C, Budman DR, Henderson IC, Citron ML, et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B experience. J Clin Oncol. 2007;25(24):3699–704.

    Article  CAS  PubMed  Google Scholar 

  70. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(25):3808–15.

    Article  CAS  Google Scholar 

  71. Bandos H, Melnikow J, Rivera DR, Swain SM, Sturtz K, Fehrenbacher L, et al. Long-term peripheral neuropathy in breast cancer patients treated with adjuvant chemotherapy: NRG oncology/NSABP B-30. J Natl Cancer Inst. 2018;110(2)

    Google Scholar 

  72. Hershman DL, Till C, Wright JD, Awad D, Ramsey SD, Barlow WE, et al. Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in southwest oncology group clinical trials. J Clin Oncol. 2016;34(25):3014–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Lange M, Heutte N, Rigal O, Noal S, Kurtz JE, Lévy C, et al. Decline in cognitive function in older adults with early-stage breast cancer after adjuvant treatment. Oncologist. 2016;21(11):1337–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Hurria A, Soto-Perez-de-Celis E, Allred JB, Cohen HJ, Arsenyan A, Ballman K, et al. Functional decline and resilience in older women receiving adjuvant chemotherapy for breast cancer. J Am Geriatr Soc. 2019;67(5):920–7.

    Article  PubMed  Google Scholar 

  75. Hopkins JO, Allred J, Hurria A, Jatoi A, Lafky JM, Cohen H, et al. Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302). Breast Cancer Res Treat. 2017;166(3):793–808.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29(25):3457–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J, et al. Predicting the risk of chemotherapy toxicity in older patients: the chemotherapy risk assessment scale for high-age patients (CRASH) score. Cancer. 2012;118(13):3377–86.

    Article  PubMed  Google Scholar 

  78. Hurria A, Magnuson A, Gross CP, Tew WP, Klepin HD, Wildes TM, et al. Abstract GS6-04: development and validation of a chemotherapy toxicity (chemo Tox) risk score for older patients (pts) with breast cancer (BC) receiving adjuvant/neoadjuvant treatment (adjuvant Tx): a R01 and BCRF funded prospective multicenter study. Cancer Res. 2019;79(Suppl 4):GS6-04.

    Article  Google Scholar 

  79. Jones S, Holmes FA, O’Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735. J Clin Oncol. 2009;27(8):1177–83.

    Article  CAS  PubMed  Google Scholar 

  80. Caparica R, Bruzzone M, Poggio F, Ceppi M, de Azambuja E, Lambertini M. Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials. Breast Cancer Res Treat. 2019;174(1):27–37.

    Article  CAS  PubMed  Google Scholar 

  81. Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, et al. Adjuvant Capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147–59.

    Article  CAS  PubMed  Google Scholar 

  82. Christiansen P, Bjerre K, Ejlertsen B, Jensen MB, Rasmussen BB, Lænkholm AV, et al. Mortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in Denmark. J Natl Cancer Inst. 2011;103(18):1363–72.

    Article  CAS  PubMed  Google Scholar 

  83. Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341–52.

    Google Scholar 

  84. Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen MB, Ejlertsen B, de Azambuja E, et al. Adjuvant Letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor-positive breast cancer: long-term follow-up of the BIG 1-98 trial. J Clin Oncol. 2019;37(2):105–14.

    Article  CAS  PubMed  Google Scholar 

  85. Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;103(17):1299–309.

    Article  CAS  PubMed  Google Scholar 

  86. Matthews A, Stanway S, Farmer RE, Strongman H, Thomas S, Lyon AR, et al. Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review. BMJ. 2018;363:k3845.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Hamood R, Hamood H, Merhasin I, Keinan-Boker L. Diabetes after hormone therapy in breast cancer survivors: a case-cohort study. J Clin Oncol. 2018;36(20):2061–9.

    Article  PubMed  Google Scholar 

  88. Ganz PA, Petersen L, Bower JE, Crespi CM. Impact of adjuvant endocrine therapy on quality of life and symptoms: observational data over 12 months from the mind-body study. J Clin Oncol. 2016;34(8):816–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Hong N, Yoon HG, Seo DH, Park S, Kim SI, Sohn JH, et al. Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: a propensity score-matched cohort study. Eur J Cancer. 2017;82:103–14.

    Article  CAS  PubMed  Google Scholar 

  90. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386(10001):1353–61.

    Google Scholar 

  91. Mamounas EP, Jeong J-H, Wickerham DL, Smith RE, Ganz PA, Land SR, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(12):1965–71.

    Article  CAS  Google Scholar 

  92. Jin H, Tu D, Zhao N, Shepherd LE, Goss PE. Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. J Clin Oncol. 2012;30(7):718–21.

    Article  CAS  PubMed  Google Scholar 

  93. Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group trial 6a. J Natl Cancer Inst. 2007;99(24):1845–53.

    Article  CAS  PubMed  Google Scholar 

  94. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17):1262–71.

    Article  CAS  PubMed  Google Scholar 

  95. Mamounas EP, Bandos H, Lembersky BC, Jeong J-H, Geyer CE, Rastogi P, et al. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(1):88–99.

    Article  CAS  PubMed  Google Scholar 

  96. Tjan-Heijnen VCG, van Hellemond IEG, Peer PGM, Swinkels ACP, Smorenburg CH, van der Sangen MJC, et al. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. Lancet Oncol. 2017;18(11):1502–11.

    Article  CAS  PubMed  Google Scholar 

  97. Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Putter H, van den Bosch J, et al. Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL trial (BOOG 2006-05). J Natl Cancer Inst. 2018;110(1)

    Google Scholar 

  98. Gray R. Abstract GS3-03: effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: an EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women. Cancer Res. 2019;79(Suppl 4) GS3-03-GS3

    Google Scholar 

  99. Goldvaser H, Barnes TA, Šeruga B, Cescon DW, Ocaña A, Ribnikar D, et al. Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2018;110(1)

    Google Scholar 

  100. Soto-Perez-De-Celis E, Loh KP, Baldini C, Battisti NML, Chavarri-Guerra Y, De Glas NA, et al. Targeted agents for HER2-positive breast cancer in older adults: current and future perspectives. Expert Opin Investig Drugs. 2018;27(10):787–801.

    Article  CAS  PubMed  Google Scholar 

  101. Vaz-Luis I, Keating NL, Lin NU, Lii H, Winer EP, Freedman RA. Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study. J Clin Oncol. 2014;32(9):927–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Cadoo KA, Morris PG, Cowell EP, Patil S, Hudis CA, McArthur HL. Adjuvant chemotherapy and Trastuzumab is safe and effective in older women with small, node-negative, HER2-positive early-stage breast cancer. Clin Breast Cancer. 2016;16(6):487–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Brollo J, Curigliano G, Disalvatore D, Marrone BF, Criscitiello C, Bagnardi V, et al. Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials. Cancer Treat Rev. 2013;39(1):44–50.

    Article  CAS  PubMed  Google Scholar 

  104. Reeder-Hayes KE, Meyer AM, Hinton SP, Meng K, Carey LA, Dusetzina SB. Comparative toxicity and effectiveness of Trastuzumab-based chemotherapy regimens in older women with early-stage breast cancer. J Clin Oncol. 2017;35(29):3298–305.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Thavendiranathan P, Abdel-Qadir H, Fischer HD, Camacho X, Amir E, Austin PC, et al. Breast cancer therapy-related cardiac dysfunction in adult women treated in routine clinical practice: a population-based cohort study. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(19):2239–46.

    Article  Google Scholar 

  106. Romond EH, Jeong J-H, Rastogi P, Swain SM, Geyer CE, Ewer MS, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(31):3792–9.

    Article  CAS  Google Scholar 

  107. Chavez-MacGregor M, Zhang N, Buchholz TA, Zhang Y, Niu J, Elting L, et al. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol. 2013;31(33):4222–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Serrano C, Cortés J, De Mattos-Arruda L, Bellet M, Gómez P, Saura C, et al. Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol. 2012;23(4):897–902.

    Article  CAS  PubMed  Google Scholar 

  109. Earl HM, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, et al. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet. 2019;393(10191):2599–612.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol. 2013;14(8):741–8.

    Article  CAS  PubMed  Google Scholar 

  111. Joensuu H, Fraser J, Wildiers H, Huovinen R, Auvinen P, Utriainen M, et al. Effect of adjuvant Trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2-positive breast cancer: the SOLD randomized clinical trial. JAMA Oncol. 2018;4(9):1199–206.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Jones SE, Collea R, Paul D, Sedlacek S, Favret AM, Gore I Jr, et al. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. Lancet Oncol. 2013;14(11):1121–8.

    Article  CAS  PubMed  Google Scholar 

  113. Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, et al. Seven-year follow-up analysis of adjuvant paclitaxel and Trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37(22):1868–75.

    Article  CAS  Google Scholar 

  114. Dall P, Koch T, Göhler T, Selbach J, Ammon A, Eggert J, et al. Trastuzumab without chemotherapy in the adjuvant treatment of breast cancer: subgroup results from a large observational study. BMC Cancer. 2018;18(1):51.

    Article  PubMed  PubMed Central  Google Scholar 

  115. von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, et al. Adjuvant Pertuzumab and Trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377(2):122–31.

    Article  Google Scholar 

  116. Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17(6):791–800.

    Article  CAS  PubMed  Google Scholar 

  117. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Waldron-Lynch M, et al. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer. 2018;89:27–35.

    Article  CAS  PubMed  Google Scholar 

  118. von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab Emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–28.

    Article  Google Scholar 

  119. Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(3):367–77.

    Article  CAS  PubMed  Google Scholar 

  120. Battisti NML, De Glas N, Sedrak MS, Loh KP, Liposits G, Soto-Perez-de-Celis E, et al. Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: young International Society of Geriatric Oncology review paper. Ther Adv Med Oncol. 2018;10:1758835918809610.

    Article  PubMed  PubMed Central  Google Scholar 

  121. Howie LJ, Singh H, Bloomquist E, Wedam S, Amiri-Kordestani L, Tang S, et al. Outcomes of older women with hormone receptor-positive, human epidermal growth factor receptor-negative metastatic breast cancer treated with a CDK4/6 inhibitor and an aromatase inhibitor: an FDA pooled analysis. J Clin Oncol. 2019;37(36):3475–83.

    Article  CAS  PubMed  Google Scholar 

  122. Rugo HS, Turner NC, Finn RS, Joy AA, Verma S, Harbeck N, et al. Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. Eur J Cancer. 2018;101:123–33.

    Article  CAS  PubMed  Google Scholar 

  123. Sonke GS, Hart LL, Campone M, Erdkamp F, Janni W, Verma S, et al. Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Res Treat. 2018;167(3):659–69.

    Article  CAS  PubMed  Google Scholar 

  124. DeLaurentiis M, Borstnar S, Campone M, Warner E, Bofill S, Jacot W, et al. Interim results from the full population of the phase 3b CompLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2– advanced breast cancer (ABC). J Clin Oncol. 2019;37(suppl 15):1041.

    Article  Google Scholar 

  125. Pritchard KI, Burris HA 3rd, Ito Y, Rugo HS, Dakhil S, Hortobagyi GN, et al. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer. 2013;13(6):421–32.e8.

    Article  CAS  PubMed  Google Scholar 

  126. Jerusalem G, Mariani G, Ciruelos EM, Martin M, Tjan-Heijnen VC, Neven P, et al. Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET). Ann Oncol. 2016;27(9):1719–25.

    Article  CAS  PubMed  Google Scholar 

  127. Brain E, Caillet P, de Glas N, Biganzoli L, Cheng K, Lago LD, et al. HER2-targeted treatment for older patients with breast cancer: an expert position paper from the International Society of Geriatric Oncology. J Geriatr Oncol. 2019;10(6):1003–13.

    Article  PubMed  Google Scholar 

  128. Wildiers H, Tryfonidis K, Dal Lago L, Vuylsteke P, Curigliano G, Waters S, et al. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the elderly task force/breast cancer group. Lancet Oncol. 2018;19(3):323–36.

    Article  CAS  PubMed  Google Scholar 

  129. Rimawi M, Ferrero J-M, de la Haba-Rodriguez J, Poole C, De Placido S, Osborne CK, et al. First-line Trastuzumab plus an aromatase inhibitor, with or without Pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(28):2826–35.

    Article  CAS  Google Scholar 

  130. Cardoso F, Bedard PL, Winer EP, Pagani O, Senkus-Konefka E, Fallowfield LJ, et al. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst. 2009;101(17):1174–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  131. Muss H, Cortes J, Vahdat LT, Cardoso F, Twelves C, Wanders J, et al. Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer. Oncologist. 2014;19(4):318–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  132. Leo S, Arnoldi E, Repetto L, Coccorullo Z, Cinieri S, Fedele P, et al. Eribulin Mesylate as third or subsequent line chemotherapy for elderly patients with locally recurrent or metastatic breast cancer: a multicentric observational study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE. Oncologist. 2019;24(6):e232–e40.

    Article  CAS  PubMed  Google Scholar 

  133. Aapro M, Tjulandin S, Bhar P, Gradishar W. Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysis. Breast. 2011;20(5):468–74.

    Article  PubMed  Google Scholar 

  134. Hind D, Wyld L, Beverley CB, Reed MW. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev. 2006;1:Cd004272.

    Google Scholar 

  135. Morgan JL, Reed MW, Wyld L. Primary endocrine therapy as a treatment for older women with operable breast cancer – a comparison of randomised controlled trial and cohort study findings. Eur J Surg Oncol. 2014;40(6):676–84.

    Article  CAS  PubMed  Google Scholar 

  136. Chakrabarti J, Kenny FS, Syed BM, Robertson JF, Blamey RW, Cheung KL. A randomised trial of mastectomy only versus tamoxifen for treating elderly patients with operable primary breast cancer-final results at 20-year follow-up. Crit Rev Oncol Hematol. 2011;78(3):260–4.

    Article  CAS  PubMed  Google Scholar 

  137. Johnston SJ, Kenny FS, Syed BM, Robertson JF, Pinder SE, Winterbottom L, et al. A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up. Ann Oncol. 2012;23(9):2296–300.

    Article  CAS  PubMed  Google Scholar 

  138. de Glas NA, Jonker JM, Bastiaannet E, de Craen AJ, van de Velde CJ, Siesling S, et al. Impact of omission of surgery on survival of older patients with breast cancer. Br J Surg. 2014;101(11):1397–404.

    Article  PubMed  Google Scholar 

  139. Syed BM, Parks RM, Cheung KL. Management of operable primary breast cancer in older women. Womens Health (Lond). 2014;10(4):405–22.

    Article  CAS  PubMed  Google Scholar 

  140. Liposits G, Loh KP, Soto-Perez-de-Celis E, Dumas L, Battisti NML, Kadambi S, et al. PARP inhibitors in older patients with ovarian and breast cancer: young International Society of Geriatric Oncology review paper. J Geriatr Oncol. 2019;10(2):337–45.

    Article  PubMed  Google Scholar 

  141. André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. N Engl J Med. 2019;380(20):1929–40.

    Article  PubMed  Google Scholar 

  142. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–21.

    Article  CAS  PubMed  Google Scholar 

  143. van Holstein Y, Kapiteijn E, Bastiaannet E, van den Bos F, Portielje J, de Glas NA. Efficacy and adverse events of immunotherapy with checkpoint inhibitors in older patients with cancer. Drugs Aging. 2019;36(10):927–38.

    Article  PubMed  PubMed Central  Google Scholar 

  144. Li J, Luo X, Cao Q, Lin Y, Xu Y, Li Q. Communication needs of cancer patients and/or caregivers: a critical literature review. J Oncol. 2020;2020:7432849.

    Article  PubMed  PubMed Central  Google Scholar 

  145. Le Saux O, Lapotre-Aurelle S, Watelet S, Castel-Kremer E, Lecardonnel C, Murard-Reeman F, et al. Systematic review of care needs for older patients treated with anticancer drugs. J Geriatr Oncol. 2018;9(5):441–50.

    Article  PubMed  Google Scholar 

  146. Wang SY, Kelly G, Gross C, Killelea BK, Mougalian S, Presley C, et al. Information needs of older women with early-stage breast cancer when making radiation therapy decisions. Int J Radiat Oncol Biol Phys. 2017;98(4):733–40.

    Article  PubMed  PubMed Central  Google Scholar 

  147. Schonberg MA, Freedman RA, Recht AR, Jacobson AR, Aliberti GM, Karamourtopoulos M, et al. Developing a patient decision aid for women aged 70 and older with early stage, estrogen receptor positive, HER2 negative, breast cancer. J Geriatr Oncol. 2019;10(6):980–6.

    Article  PubMed  Google Scholar 

  148. Lifford KJ, Edwards A, Burton M, Harder H, Armitage F, Morgan JL, et al. Efficient development and usability testing of decision support interventions for older women with breast cancer. Patient Prefer Adherence. 2019;13:131–43.

    Article  PubMed  PubMed Central  Google Scholar 

  149. Burton M, Collins KA, Lifford KJ, Brain K, Wyld L, Caldon L, et al. The information and decision support needs of older women (>75 yrs) facing treatment choices for breast cancer: a qualitative study. Psychooncology. 2015;24(8):878–84.

    Article  PubMed  Google Scholar 

  150. Ulloa JG, Hemmelgarn M, Viveros L, Odele P, Feldman NR, Ganz PA, et al. Improving breast cancer survivors’ knowledge using a patient-centered intervention. Surgery. 2015;158(3):669–75.

    Article  PubMed  Google Scholar 

  151. Arati Rao HJC. Symptom management in the elderly cancer patient: fatigue, pain, and depression. JNCI Monographs. 2004;32:150–7.

    Google Scholar 

  152. Naeim A, Aapro M, Subbarao R, Balducci L. Supportive care considerations for older adults with cancer. J Clin Oncol. 2014;32(24):2627–34.

    Article  PubMed  Google Scholar 

  153. Gerber LH, Stout N, McGarvey C, Soballe P, Shieh CY, Diao G, et al. Factors predicting clinically significant fatigue in women following treatment for primary breast cancer. Support Care Cancer. 2011;19(10):1581–91.

    Article  PubMed  Google Scholar 

  154. Fu MR, Rosedale M. Breast cancer survivors’ experiences of lymphedema-related symptoms. J Pain Symptom Manag. 2009;38(6):849–59.

    Article  Google Scholar 

  155. Radice D, Redaelli A. Breast cancer management: quality-of-life and cost considerations. PharmacoEconomics. 2003;21(6):383–96.

    Article  PubMed  Google Scholar 

  156. Turner N, Zafarana E, Becheri D, Mottino G, Biganzoli L. Breast cancer in the elderly: which lessons have we learned? Future Oncol. 2013;9(12):1871–81.

    Article  CAS  PubMed  Google Scholar 

  157. Crivellari D, Aapro M, Leonard R, von Minckwitz G, Brain E, Goldhirsch A, et al. Breast cancer in the elderly. J Clin Oncol. 2007;25(14):1882–90.

    Article  PubMed  Google Scholar 

  158. Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33(28):3199–212.

    Article  CAS  PubMed  Google Scholar 

  159. Laribi K, Badinand D, Janoray P, Benabed K, Mouysset J-L, Fabre E, et al. Filgrastim prophylaxis in elderly cancer patients in the real-life setting: a French multicenter observational study, the TULIP study. Support Care Cancer. 2019;27(11):4283–92.

    Article  PubMed  PubMed Central  Google Scholar 

  160. Varghese F, Wong J. Breast cancer in the elderly. Surg Clin North Am. 2018;98(4):819–33.

    Article  PubMed  Google Scholar 

  161. Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G, et al. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res. 2010;12(1):R1.

    Article  PubMed  PubMed Central  Google Scholar 

  162. Candido Dos Reis FJ, Wishart GC, Dicks EM, Greenberg D, Rashbass J, Schmidt MK, et al. An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation. Breast Cancer Res. 2017;19(1):58.

    Article  PubMed  PubMed Central  Google Scholar 

  163. de Glas NA, Bastiaannet E, Engels CC, de Craen AJ, Putter H, van de Velde CJ, et al. Validity of the online PREDICT tool in older patients with breast cancer: a population-based study. Br J Cancer. 2016;114(4):395–400.

    Article  PubMed  PubMed Central  Google Scholar 

  164. Verduzco-Aguirre HC, Gomez-Moreno C, Chavarri-Guerra Y, Soto-Perez-de-Celis E. Predicting life expectancy for older adults with cancer in clinical practice: implications for shared decision-making. Curr Oncol Rep. 2019;21(8):68.

    Article  PubMed  Google Scholar 

  165. Lux MP, Bayer CM, Loehberg CR, Fasching PA, Schrauder MG, Bani MR, et al. Shared decision-making in metastatic breast cancer: discrepancy between the expected prolongation of life and treatment efficacy between patients and physicians, and influencing factors. Breast Cancer Res Treat. 2013;139(2):429–40.

    Article  PubMed  Google Scholar 

  166. Dean LT, Gehlert S, Neuhouser ML, Oh A, Zanetti K, Goodman M, et al. Social factors matter in cancer risk and survivorship. Cancer Causes Control. 2018;29(7):611–8.

    Article  PubMed  PubMed Central  Google Scholar 

  167. Organization WH. World conference on social determinants of health: case studies on social determinants. 2014. Available from: http://www.who.int/sdhconference/resources/case_studies/en/.

  168. Coughlin SS. Social determinants of breast cancer risk, stage, and survival. Breast Cancer Res Treat. 2019;177(3):537–48.

    Article  PubMed  Google Scholar 

  169. Montroni I, Rocchi M, Santini D, Ceccarelli C, Ghignone F, Zattoni D, et al. Has breast cancer in the elderly remained the same over recent decades? A comparison of two groups of patients 70years or older treated for breast cancer twenty years apart. J Geriatr Oncol. 2014;5(3):260–5.

    Article  PubMed  Google Scholar 

  170. Gosain R, Pollock Y, Jain D. Age-related disparity: breast cancer in the elderly. Curr Oncol Rep. 2016;18(11):69.

    Article  PubMed  Google Scholar 

  171. Joyce DP, O’Neill C, Heneghan HM, Curran C, Barry K, Sweeney K, et al. The changing cost of breast cancer care: lessons from a centralised modern cancer centre. Ir J Med Sci. 2019;188(2):409–14.

    Article  PubMed  Google Scholar 

  172. Rosenzweig M, West M, Matthews J, Stokan M, Yoojin Kook YK, Gallups S, et al. Financial toxicity among women with metastatic breast cancer. Oncol Nurs Forum. 2019;46(1):83–91.

    PubMed  Google Scholar 

  173. Khera N. Reporting and grading financial toxicity. J Clin Oncol. 2014;32(29):3337–8.

    Article  PubMed  Google Scholar 

  174. Greenup RA, Blitzblau RC, Houck KL, Sosa JA, Horton J, Peppercorn JM, et al. Cost implications of an evidence-based approach to radiation treatment after lumpectomy for early-stage breast cancer. J Oncol Pract. 2017;13(4):e283–e90.

    Article  PubMed  PubMed Central  Google Scholar 

  175. Meneses K, Azuero A, Hassey L, McNees P, Pisu M. Does economic burden influence quality of life in breast cancer survivors? Gynecol Oncol. 2012;124(3):437–43.

    Article  PubMed  Google Scholar 

  176. Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney DW, Blum D, et al. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol. 2015;33(23):2563–77.

    Article  PubMed  PubMed Central  Google Scholar 

  177. Souza JAD, Yap BJ. Relationship between financial toxicity and health-related quality of life in patients with advanced solid tumors. J Clin Oncol. 2014;32(Suppl 30):31.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

    Gretell Henríquez, Yanin Chavarri-Guerra & Enrique Soto-Perez-de-Celis

  2. Department of Medicine - Breast Unit, The Royal Marsden NHS Foundation Trust, London, UK

    Nicolò Matteo Luca Battisti

Authors
  1. Gretell Henríquez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicolò Matteo Luca Battisti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yanin Chavarri-Guerra
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Enrique Soto-Perez-de-Celis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Enrique Soto-Perez-de-Celis .

Editor information

Editors and Affiliations

  1. California Association of Long Term Care Medicine, Newbury Park, CA, USA

    Michael R. Wasserman

  2. Betty Irene Moore School of Nursing, University of California, Davis, Sacramento, CA, USA

    Debra Bakerjian

  3. Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA

    Sunny Linnebur

  4. Division of Geriatrics, SUNY Upstate Medical University, Syracuse, NY, USA

    Sharon Brangman

  5. Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy

    Matteo Cesari

  6. Section of Geriatric Medicine, Division of Internal Medicine, Department of Medicine, Cedars-Sinai, Beverly Hills, CA, USA

    Sonja Rosen

Section Editor information

  1. Department of Medicine, Geriatrics Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Armin Shahrokni MD

Rights and permissions

Reprints and permissions

Copyright information

© 2024 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Henríquez, G., Battisti, N.M.L., Chavarri-Guerra, Y., Soto-Perez-de-Celis, E. (2024). Breast Cancer. In: Wasserman, M.R., Bakerjian, D., Linnebur, S., Brangman, S., Cesari, M., Rosen, S. (eds) Geriatric Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-74720-6_77

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-74720-6_77

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-74719-0

  • Online ISBN: 978-3-030-74720-6

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation